NYSE American - Delayed Quote USD

OS Therapies Incorporated (OSTX)

Compare

4.9700

-0.1500

(-2.93%)

At close: January 10 at 4:00:00 PM EST

5.0150

+0.05

+(0.91%)

After hours: January 10 at 6:20:25 PM EST

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, January 02, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that its Chair & CEO Paul Romness has accepted an invitation to attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA taking place on January 13-16, 2025 in San Francisco, CA. This premier conference is the largest and most informative health care investment symposium in the indus

Business Wire 10 days ago

OSTX
-2.93%
OS Therapies Announces Closing of $6 Million Private Placement

NEW YORK, December 31, 2024--OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or the "Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced the closing of a private placement financing, raising approximately $6 million in gross proceeds for the Company, before deducting offering-related expenses. The Company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory mi

Business Wire 11 days ago

OSTX
-2.93%
OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online

Digital Marketing Campaign to Highlight Clinical-Stage Cancer Innovation OST-HER2 that activates cellular immunity against HER2+ cancer OS Therapies Joins the B2i Digital Featured Companies Program NEW YORK - (NewMediaWire) - December 26, 2024 - OS...

NewMediaWire 17 days ago

OSTX
-2.93%
OS Therapies to sell 1.5M units at $4.00 in private placement

OS Therapies (OSTX) announced that it has entered into securities purchase agreements with investors to sell 1.5M units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock initially convertible into one share of common stock and one warrant to purchase one share of common stock, expected to yield gross proceeds to the company of $6M, before deducting offering-related expenses. The conversion price of the Preferred Stock into shares

TipRanks 18 days ago

OSTX
-2.93%
OS Therapies Announces Pricing of $6 Million Private Placement

NEW YORK, December 24, 2024--OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has entered into securities purchase agreements with investors to sell 1.5 million units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock ("the Preferred Stock") initially convertible into one share of common stock and one

Business Wire 19 days ago

OSTX
-2.93%
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

NEW YORK, November 15, 2024--OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update.

Business Wire last month

OSTX
-2.93%
OS Therapies to Present at The Spartan Capital Investor Conference

NEW YORK, November 04, 2024--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at The Spartan Capital Investor Conference. The conference is being held on November 4, 2024 at the Pierre Hotel in New York. The Company’s participation aligns with our comm

Business Wire 2 months ago

OSTX
-2.93%
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

NEW YORK, October 30, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET.

Business Wire 2 months ago

OSTX
-2.93%
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

NEW YORK, October 28, 2024--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company’s Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in comm

Business Wire 2 months ago

OSTX
-2.93%
OS Therapies to Present at the LD Micro Main Event XVII

NEW YORK, October 24, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Business Wire 2 months ago

OSTX
-2.93%
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

NEW YORK, October 17, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, will be presenting at the 2024 Maxim Healthcare Virtual Summit. The summit is being held virtually on October 15 – 17, 2024.

Business Wire 2 months ago

OSTX
-2.93%
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

NEW YORK, October 03, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation at 52 weeks and the treatment period for the clinical trial has now ended. The Company is preparing to re

Business Wire 3 months ago

OSTX
-2.93%
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

NEW YORK, September 13, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company’s proprietary SiLinker™ technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will

Business Wire 3 months ago

OSTX
-2.93%
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer Strong safety profile for FRA-H with no loss ...

ACCESSWIRE 3 months ago

OSTX
-2.93%
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

NEW YORK, September 05, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. The Company’s President & CEO Paul Romness, MPH, will deliver a virtual presentation highlighting the Company’s potentially pivotal fully-enrolled Phase 2b

Business Wire 4 months ago

OSTX
-2.93%
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

NEW YORK, August 29, 2024--OS Therapies Incorporated (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dose. This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Eve

Business Wire 4 months ago

OSTX
-2.93%
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

NEW YORK, August 22, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company’s tunable ADC platform leveraging its proprietary pH-sensitive SiLinker™ silicone linker techn

Business Wire 4 months ago

OSTX
-2.93%
OS Therapies Clarifies CUSIP of Common Stock

NEW YORK, August 22, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarification for market participants, specifically brokerage firms, regarding the Committee on Uniform Securities Identification Procedures (CUSIP) identifier of the Company’s common stock.

Business Wire 4 months ago

OSTX
-2.93%
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

ROCKVILLE, Md., August 19, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has been accepted into Johnson & Johnson Innovation – JLABS. Through membership of JLABS, OS Therapies aims to further develop and enter the clinic with its tunable Antibody Drug Conjugate (ADC) linker-based platform that relies on pH sensitive linkers & coating technology to reduce off-targe

Business Wire 4 months ago

OSTX
-2.93%
OS Therapies Reports Second Quarter 2024 Financial Results

Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all reported outstanding preferred shares and debt into ...

ACCESSWIRE 4 months ago

OSTX
-2.93%

Performance Overview

Return	OSTX	S&P 500
YTD	+5.74%	-1.35%
1-Year	+24.25%	+22.51%
3-Year	+24.25%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OS Therapies Incorporated (OSTX)

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

OS Therapies Announces Closing of $6 Million Private Placement

OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online

OS Therapies to sell 1.5M units at $4.00 in private placement

OS Therapies Announces Pricing of $6 Million Private Placement

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies to Present at The Spartan Capital Investor Conference

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

OS Therapies Clarifies CUSIP of Common Stock

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

OS Therapies Reports Second Quarter 2024 Financial Results

Performance Overview